Some risk management issues in teriflunomide treatment of patients with remitting multiple sclerosis

New immunomodulatory drugs for the treatment of multiple sclerosis are emerging today in the pharmaceutical market. In Russia, new first line preparation - teriflunomide 14 mg in tablet form - was recently granted approval for the treatment of patients with remitting MS. The drug demonstrated good tolerability, efficacy and relative safety in long-term clinical trials. The article discusses an algorithm for the management of patients with RMS aimed at reducing the risk of adverse events associated with teriflunomide therapy.